SCHEMBL21122016

SCHEMBL21122016

C#Cc1cc(C#C)c(O)c(C(=O)O)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1C2 P52895 6/20 0.40
AKR1C1 Q04828 6/20 0.40
AKR1C4 P17516 3/20 0.37
AKR1C3 P42330 3/20 0.37
MEN1 O00255 3/20 0.36
KMT2A Q03164 3/20 0.36
HTT P42858 2/20 0.36
PDE4A P27815 1/20 0.36
BLVRB P30043 1/20 0.36
KDR P35968 1/20 0.36
HNF4A P41235 1/20 0.36
HSD17B10 Q99714 4/20 0.35
HPGD P15428 3/20 0.35
THRB P10828 2/20 0.35
CYP2C9 P11712 1/20 0.35
TSHR P16473 1/20 0.35
ALOX12 P18054 1/20 0.35
ATIC P31939 1/20 0.35
ADRA2B P18089 1/20 0.35
ADRA2C P18825 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29451088 1.00 AKR1C2 (0.40) AKR1C2AKR1C1AKR1C4AKR1C3MEN1
SCHEMBL9349821 0.79 HMGB1 (0.53) AKR1C2AKR1C1AKR1C4AKR1C3MEN1
SCHEMBL2810137 0.79 CYP1A1 (0.34)
SCHEMBL9349088 0.77 ALDH1A1 (0.42) AKR1C2AKR1C1AKR1C4AKR1C3MEN1
SCHEMBL689828 0.74 HNF4A (0.41) AKR1C2AKR1C1AKR1C3MEN1KMT2A
SCHEMBL689510 0.74 CYP1A2 (0.39) MEN1KMT2AHTTPDE4ABLVRB
SCHEMBL4959352 0.73 XDH (0.41) AKR1C2AKR1C1AKR1C4AKR1C3MEN1
SCHEMBL21159417 0.73 PTPN1 (0.36) AKR1C2AKR1C1AKR1C4AKR1C3MEN1
SCHEMBL2536166 0.71 HNF4A (0.62) MEN1KMT2AHTTPDE4ABLVRB
SCHEMBL541999 0.69 HNF4A (0.43) MEN1KMT2AHNF4AHSD17B10CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025137293-A2 ENHANCEMENT OF NUCLEIC ACID POLYMERIZATION BY AROMATIC COMPOUNDS Roche Sequencing Solutions, Inc. (US) 2025-06-26 WO disclosed
US-20250075265-A1 ENHANCEMENT OF NUCLEIC ACID POLYMERIZATION BY AROMATIC COMPOUNDS ROCHE SEQUENCING SOLUTIONS INC (US) 2025-03-06 US disclosed
US-11970731-B2 Enhancement of nucleic acid polymerization by aromatic compounds Roche Sequencing Solutions, Inc. (US) 2024-04-30 US disclosed
EP-3735409-B1 ENHANCEMENT OF NUCLEIC ACID POLYMERIZATION BY AROMATIC COMPOUNDS STRATOS GENOMICS INC (US) 2023-06-21 EP disclosed
EP-3735409-B1 ENHANCEMENT OF NUCLEIC ACID POLYMERIZATION BY AROMATIC COMPOUNDS STRATOS GENOMICS INC (US) 2023-06-21 EP disclosed
EP-3994262-A1 ENHANCEMENT OF NUCLEIC ACID POLYMERIZATION BY AROMATIC COMPOUNDS Stratos Genomics Inc. (US) 2022-05-11 EP disclosed
US-20220112548-A1 ENHANCEMENT OF NUCLEIC ACID POLYMERIZATION BY AROMATIC COMPOUNDS Roche Sequencing Solutions, Inc. 2022-04-14 US disclosed
CN-114144520-A Enhanced nucleic acid polymerization by aromatic compounds 斯特拉托斯基因公司 2022-03-04 CN disclosed
US-20210062251-A1 ENHANCEMENT OF NUCLEIC ACID POLYMERIZATION BY AROMATIC COMPOUNDS Roche Sequencing Solutions, Inc. 2021-03-04 US disclosed
US-20210062251-A1 ENHANCEMENT OF NUCLEIC ACID POLYMERIZATION BY AROMATIC COMPOUNDS Roche Sequencing Solutions, Inc. 2021-03-04 US disclosed
WO-2020263703-A1 ENHANCEMENT OF NUCLEIC ACID POLYMERIZATION BY AROMATIC COMPOUNDS STRATOS GENOMICS, INC. (US) 2020-12-30 WO disclosed
WO-2020263703-A1 ENHANCEMENT OF NUCLEIC ACID POLYMERIZATION BY AROMATIC COMPOUNDS STRATOS GENOMICS, INC. (US) 2020-12-30 WO disclosed
EP-3735409-A1 ENHANCEMENT OF NUCLEIC ACID POLYMERIZATION BY AROMATIC COMPOUNDS Stratos Genomics Inc. (US) 2020-11-11 EP disclosed
CN-111771001-A Enhanced nucleic acid polymerization by aromatic compounds 斯特拉托斯基因公司 2020-10-13 CN disclosed
WO-2019135975-A1 ENHANCEMENT OF NUCLEIC ACID POLYMERIZATION BY AROMATIC COMPOUNDS STRATOS GENOMICS INC. (US) 2019-07-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210062251-A1 ENHANCEMENT OF NUCLEIC ACID POLYMERIZATION BY AROMATIC COMPOUNDS POLN, POLB, POLRMT AKR1C2 2097/4885AKR1C1 2290/4885AKR1C4 2052/4885
US-11970731-B2 Enhancement of nucleic acid polymerization by aromatic compounds POLN, POLB, POLRMT AKR1C2 2097/4885AKR1C1 2290/4885AKR1C4 2052/4885
US-20250075265-A1 ENHANCEMENT OF NUCLEIC ACID POLYMERIZATION BY AROMATIC COMPOUNDS POLN, POLB, POLRMT AKR1C2 2097/4885AKR1C1 2290/4885AKR1C4 2052/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.